Montelukast Paediatric 5 Mg 30 Tap is indicated for the treatment of asthma as add-on therapy for patients aged 6 to 14 years with mild to moderate persistent asthma.
It is particularly useful for those inadequately controlled on inhaled corticosteroids and where 'as-needed' short-acting β-agonists provide inadequate clinical control.
Montelukast may also serve as an alternative treatment option to low-dose inhaled corticosteroids for patients with mild persistent asthma who lack a recent history of serious asthma attacks.
Additionally, it is indicated for the prophylaxis of exercise-induced bronchoconstriction, helping to prevent asthma symptoms during physical activity.
This medication is easy to use and can significantly improve the quality of life for children and adolescents suffering from asthma.
